STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements

Rhea-AI Summary

STRATA Skin Sciences (NASDAQ: SSKN) reports significant success with its Elevate 360 (E360) consulting services platform, which helps partner clinics optimize their XTRAC laser treatment operations. The program focuses on implementing best practices in marketing, reimbursement, and patient retention.

Since early 2025, 99 out of 844 clinics have adopted E360, achieving an average 7% year-over-year growth. A notable case study showed one partner's revenue contribution to STRATA increasing from $10,500 in H1 2024 to $61,800 in H1 2025, while expanding from 2 to 9 clinics after implementing E360.

The program helps clinics optimize patient referrals, insurance reimbursement, scheduling, and follow-up visits, particularly beneficial with recent reimbursement improvements for vitiligo and auto-immune skin conditions.

Positive

• E360 program adoption led to 7% average year-over-year growth for participating clinics
• Case study shows 489% revenue increase ($10,500 to $61,800) for partner clinics in H1 2025 vs H1 2024
• Partner clinic expansion from 2 to 9 locations after E360 implementation
• Recent reimbursement improvements expand treatment indications, increasing market potential

Negative

• Only 99 out of 844 clinics (11.7%) have adopted the E360 program so far
• Pre-E360 case study showed poor conversion rate with only 6 treated patients out of 160 prescribed treatments

Insights

Healthcare Business Analyst

STRATA's Elevate 360 consulting program drives significant revenue growth, with clinic partnerships showing 7% YoY growth and specific case examples of 5.9x revenue increases.

STRATA Skin Sciences' Elevate 360 (E360) consulting program is demonstrating meaningful operational impact for both the company and its partner clinics. The program, which focuses on implementing best practices in marketing, reimbursement optimization, and patient retention for clinics using STRATA's XTRAC excimer laser technology, has been adopted by 99 of approximately 844 partner clinics since early 2025. These participating clinics have achieved an average 7% year-over-year growth.

The program addresses critical operational gaps in the patient journey. In one striking case study, a partner with two clinics generated only $10,500 in treatment revenue for STRATA during H1 2024 despite having 880 relevant patients and securing insurance benefits for 132 patients. The core issue identified was poor patient scheduling and follow-up. After implementing E360 in Q3 2024, this partner expanded to nine clinics and generated $61,800 in revenue for STRATA in H1 2025—a 489% increase.

What makes this particularly significant is how E360 targets the disconnect between patient identification, insurance verification, and actual treatment delivery. The case study revealed that despite identifying 160 prescription-eligible patients and securing insurance benefits for 132, only 6 patients received treatment pre-E360 implementation—a conversion rate of just 4.5%. This signals enormous untapped revenue potential for both STRATA and its clinic partners through improved operational efficiency.

The E360 program also strategically positions STRATA to capitalize on recent reimbursement improvements that expanded treatment indications for XTRAC lasers to include vitiligo and auto-immune associated skin conditions, creating additional revenue pathways. By transforming partner clinics from potential churn risks into growth engines through systematic operational enhancements, STRATA is strengthening its recurring revenue model while increasing partner dependency on its services.

Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces growth in business operations of partner clinics that have adopted its Elevate 360 (“E360”) consulting services platform, designed to help partner clinics maximize its revenue potential in providing treatment with the Company’s XTRAC excimer laser technology through the adoption of best practices programs, including marketing, reimbursement, and patient retention tactics. These successes have also fueled new clinic partnership agreements with STRATA.

Dr. Dolev Rafaeli, Strata’s President and CEO commented, “While adding XTRAC to their dermatology practice helps these clinics maintain optimal care for its patients, many of these operators could benefit from optimization in their business and marketing practices. We developed the E360 program to help them better utilize and expand their business operations with a goal to maximize their revenue opportunities and attract and retain patients with the implementation of a variety of best practice initiatives. Best practices provided under our E360 program include turn-key marketing solutions, optimizing and expansion of business systems, and others that have quickly shown improvement in partner clinic top and bottom lines.

“Specifically, we help our partner clinics seamlessly complete the end-to-end process of providing treatment, from identifying new patient referrals, securing reimbursement and patient insurance benefits for these procedures, and making sure these patients are actually scheduled for treatment. We also help with scheduling follow up patient visits to maintain successful patient outcomes, promoting patient retention. We believe that nothing should stop these businesses from significantly growing, and we are providing them with the resources they need to do so,” added Dr. Rafaeli.

Since the beginning of 2025, 99 of the approximately 844 clinics that operate under the Strata’s XTRAC usage agreement have entered the program, resulting in an average 7% growth year over year for those businesses completing the review. More clinics are signing up for the Elevate 360 program as they observe the revenue increases for program participants.

One such partner with two clinics observed a total revenue of $10,500 paid to Strata from treatments during the first half of 2024. This performance made these clinics good candidates for removal and termination of the usage agreement, despite having consulted over 880 patients with relevant indications during that period. Over 160 of these patients had been prescribed for the XTRAC treatment, with Strata having been able to secure insurance benefits for 132. However, only six of these patients were actually treated during that period.

After adopting the E360 program in Q3 2024, realizing that the specific breakdown involved lack of patient scheduling and call-back by the clinics’ operation staff, that partner has since expanded to nine clinics resulting in first half 2025 revenue of $61,800 for Strata, with expectations of continued growth as the new clinics ramp-up and realize their existing patient population, which represents what the Company believes is only a fraction of the potential value the E360 program offers.

“We developed E360 to help realize significant growth opportunities for both STRATA and our clinic partners, including from the recently announced improvements in reimbursement that expanded indications for which treatment with our XTRAC lasers can be applied, such as vitiligo and auto-immune associated skin conditions. We look forward to the continued demonstration of the benefits that E360 offers our clinic partners in optimizing business practices, as we help to meet patient demand and realize the market potential,” concluded Dr. Rafaeli.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

FAQ

What is STRATA Skin Sciences' Elevate 360 (E360) consulting program?

E360 is a consulting services platform that helps partner clinics maximize revenue potential with XTRAC laser technology through marketing, reimbursement, and patient retention best practices.

How much revenue growth did SSKN's E360 program generate for partner clinics?

Partner clinics implementing E360 achieved an average 7% year-over-year growth, with one case study showing revenue increase from $10,500 to $61,800 in H1 2025.

How many clinics have adopted STRATA's E360 program in 2025?

99 out of 844 clinics (11.7%) operating under STRATA's XTRAC usage agreement have adopted the E360 program since early 2025.

What services does STRATA's E360 program provide to partner clinics?

E360 provides turn-key marketing solutions, business system optimization, patient referral management, insurance reimbursement assistance, and scheduling optimization for initial and follow-up treatments.

How does SSKN's E360 program impact clinic expansion?

The program demonstrates significant impact on clinic expansion, with one partner growing from 2 to 9 clinics after implementing E360 and showing substantial revenue growth.